Loading
A phase 1/2 trial of Aldesleukin, Avelumab, Nivolumab in metastatic cancer and melanoma, run by Aulos Bioscience, Inc., now recruiting.
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05267626 by Aulos Bioscience, Inc., with 159 participants planned, started 2022-04-04 and due to reach its primary completion in 2027-02-28. Interventions recorded: AU-007, Aldesleukin, Avelumab, Nivolumab. Conditions listed: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Avelumab, Nivolumab, Small-cell lung cancer, Melanoma.
Shares TIL therapy, Cytokines & engineered cytokines, Melanoma.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares Avelumab, Metastatic cancer (cancer that has spread).
Shares TIL therapy, Melanoma.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares TIL therapy, Melanoma.
Shares TIL therapy, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/